285 related articles for article (PubMed ID: 37675898)
1. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
2. A Combinatorial Strategy for Targeting
Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
[No Abstract] [Full Text] [Related]
4. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
[TBL] [Abstract][Full Text] [Related]
5. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
6. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
7. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract][Full Text] [Related]
8. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
9. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
10. MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer.
ElMokh O; Taelman V; Radojewski P; Roelli MA; Stoss A; Dumont RA; Dettmer MS; Phillips WA; Walter MA; Charles RP
J Nucl Med; 2019 Jul; 60(7):917-923. PubMed ID: 30464041
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
12. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
13. Mutation based approaches to the treatment of anaplastic thyroid cancer.
McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
[TBL] [Abstract][Full Text] [Related]
14. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
15. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
Chen TY; Lorch JH; Wong KS; Barletta JA
Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
[TBL] [Abstract][Full Text] [Related]
16. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
[TBL] [Abstract][Full Text] [Related]
17. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
18. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture.
Ingeson-Carlsson C; Martinez-Monleon A; Nilsson M
Exp Cell Res; 2015 Nov; 338(2):127-35. PubMed ID: 26384551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
